Latest News and Press Releases

Oslo, 24 May 2022. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall...

Oslo (Norway), 11 May 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q1 2022 results. Please find enclosed the report and presentation. ...

Oslo (Norway), 9 May 2022 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced a...

Oslo, Norway, 4 May 2022 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's Q1 2022 interim report on Wednesday 11 May 2022, 08:30am – 09:30am CEST (local time). The...

Oslo, Norway 4 May 2022 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 25 May 2022 at 10:00am (CEST). The...

Oslo, Norway, April 28, 2022The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2021 and the report is attached, in addition to the report according to the European Single...

Oslo (Norway), 28 March 2022 – PCI Biotech (OSE: PCIB) announces today that CEO, Dr Per Walday has resigned to assume a new position. Dr Walday has a notice period of six months, and he will step down...

Oslo (Norway), 18 February 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q4 and preliminary full-year 2021 results. Please find enclosed the...

Oslo, Norway, 14 February 2022 - PCI Biotech (OSE: PCIB) invites to a presentation of the company's Q4 and preliminary full-year 2021 results on Friday 18 February 2022 at Oslo Cancer Cluster...

Oslo (Norway), 24 January 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the company has decided to stop the RELEASE study and focus their drug...